###begin article-title 0
Interleukin-13 and Its Receptors in Idiopathic Interstitial Pneumonia: Clinical Implications for Lung Function
###end article-title 0
###begin p 1
###xml 640 641 624 625 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 728 729 712 713 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 811 812 791 792 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 875 876 855 856 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 904 905 884 885 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 365 373 <span type="species:ncbi:9606">patients</span>
###xml 420 428 <span type="species:ncbi:9606">patients</span>
###xml 614 622 <span type="species:ncbi:9606">patients</span>
###xml 694 702 <span type="species:ncbi:9606">patients</span>
###xml 777 785 <span type="species:ncbi:9606">patients</span>
###xml 929 937 <span type="species:ncbi:9606">patients</span>
###xml 1056 1064 <span type="species:ncbi:9606">patients</span>
###xml 1196 1204 <span type="species:ncbi:9606">patients</span>
Idiopathic interstitial pneumonia (IIP) is characterized by varying degrees of interstitial fibrosis. IL-13 and IL-4 are strong inducers of tissue fibrosis, whereas IFN-gamma has antifibrotic potential. However, the roles of these substances in IIP remain unknown. IL-13, IL-4, and IFN-gamma were measured in the BAL fluid of 16 idiopathic pulmonary fibrosis (IPF) patients, 10 nonspecific interstitial pneumonia (NSIP) patients, and 8 normal controls. The expression of IL-13 and IL-13Ralpha1/alpha2 in lung tissues was analyzed using ELISA and immunohistochemistry. IL-13 levels were significantly higher in IPF patients than the others (P<0.05). IL-4 levels were higher in both IPF and NSIP patients than in normal controls (P<0.05), and IFN-gamma levels were lower in NSIP patients than in normal controls (P=0.047). IL-13 levels correlated inversely with FVC% (r=-0.47, P=0.043) and DLCO% (r=-0.58, P=0.014) in IPF and NSIP patients. IL-13 was strongly expressed in the smooth muscle, bronchial epithelium, alveolar macrophages and endothelium of IPF patients. IL-13Ralpha1, rather than IL-13Ralpha2, was strongly expressed in the smooth muscle, bronchial epithelium, and endothelium of IPF patients. IL-13 and its receptors may contribute to the pathogenesis of fibrosis in IIP and appear to be related to the severity of the disease.
###end p 1
###begin title 2
INTRODUCTION
###end title 2
###begin p 3
###xml 166 167 166 167 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B1">1</xref>
###xml 298 299 298 299 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B2">2</xref>
###xml 300 301 300 301 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B4">4</xref>
###xml 332 333 332 333 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B2">2</xref>
###xml 357 358 357 358 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B3">3</xref>
###xml 360 361 360 361 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B4">4</xref>
###xml 659 660 651 652 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B5">5</xref>
###xml 811 812 803 804 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B6">6</xref>
###xml 814 815 806 807 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B7">7</xref>
###xml 965 966 949 950 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B8">8</xref>
###xml 1025 1026 1001 1002 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B9">9</xref>
###xml 1028 1030 1004 1006 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B10">10</xref>
###xml 1217 1219 1185 1187 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B10">10</xref>
###xml 1221 1223 1189 1191 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B11">11</xref>
###xml 1345 1347 1309 1311 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B12">12</xref>
###xml 406 414 <span type="species:ncbi:9606">patients</span>
###xml 649 657 <span type="species:ncbi:9606">patients</span>
###xml 1375 1381 <span type="species:ncbi:9606">humans</span>
Idiopathic pulmonary fibrosis (IPF) is a progressive and usually lethal lung disease characterized by fibroblast proliferation and extracellular matrix accumulation (1). Its pathogenesis remains poorly understood but is associated with a predominance of Th2 cytokine and a paucity of Th1 cytokine (2-4). Studies on immunopathology (2) and m-RNA expression (3, 4) have revealed that the lung tissues of IPF patients show abnormally high levels of interleukin (IL)-4 and IL-5, and a low level of interferon-gamma (IFN-gamma). Flow cytometry analysis of intracellular cytokines showed a similar pattern in the bronchoalveolar lavage (BAL) cells of IPF patients (5). The role of Th2 cytokines, especially IL-4 and IL-13, in pulmonary fibrosis has been clearly demonstrated by both in vivo and in vitro experiments (6, 7). These two cytokines function via complex receptor systems that include IL-4 receptor alpha (IL-4Ralpha), and IL-13 receptor alpha1 (IL-13Ralpha1) (8). IL-13Ralpha1 binds IL-13 in a complex with IL-4Ralpha1 (9, 10). IL-13 receptor alpha2 (IL-13Ralpha2) has a short cytoplasmic tail without intracellular signaling motifs; thus, it may function as a decoy receptor that inhibits the effects of IL-13 (10, 11). The down-regulatory effect of IL-13Ralpha2 has been demonstrated in animal models with IL-13-mediated tissue fibrosis (12) but has not been shown in humans.
###end p 3
###begin p 4
###xml 176 178 176 178 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B13">13</xref>
###xml 180 182 180 182 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B14">14</xref>
###xml 287 289 287 289 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B15">15</xref>
###xml 291 293 291 293 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B16">16</xref>
###xml 655 657 655 657 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B17">17</xref>
###xml 658 660 658 660 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B20">20</xref>
IPF and nonspecific interstitial pneumonia (NSIP) are the two common types of idiopathic interstitial pneumonia (IIP). However, compared with IPF, NSIP leads to less fibrosis (13, 14) and shows a better response to anti-inflammatory agents such as steroids and anti-proliferative drugs (15, 16). Therefore, the two diseases may induce different patterns of fibrosis-related cytokines. It has already been demonstrated that NSIP and IPF lead to different levels of inflammatory cytokines and CXC chemokines, such as IL-6, IL-8, epithelial neutrophil-activating peptide 78, interferon gamma-inducible protein 10, RANTES, and monocyte chemotactic protein-1 (17-20), but little is known about how Th2 and Th1 cytokines and their receptors differ between the two conditions.
###end p 4
###begin p 5
###xml 161 169 <span type="species:ncbi:9606">patients</span>
We hypothesized that IFN-gamma, IL-4, and IL-13 may be regulated differently and that IL-13Ralpha1 and IL-13Ralpha2 may be expressed differently in IPF and NISP patients.
###end p 5
###begin p 6
###xml 104 112 <span type="species:ncbi:9606">patients</span>
To test this hypothesis, we measured IL-4, IL-13, and IFN-gamma levels in the BAL fluid of IPF and NSIP patients and normal controls, and compared IL-13Ralpha1 and IL-13Ralpha2 expression in diseased lung tissues using immunohistochemical staining.
###end p 6
###begin title 7
MATERIALS AND METHODS
###end title 7
###begin title 8
Study populations
###end title 8
###begin p 9
###xml 208 215 208 215 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T1">Table 1</xref>
###xml 301 303 301 303 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B21">21</xref>
###xml 37 45 <span type="species:ncbi:9606">patients</span>
###xml 322 330 <span type="species:ncbi:9606">patients</span>
###xml 535 543 <span type="species:ncbi:9606">patients</span>
The study population consisted of 16 patients with IPF, ten with idiopathic NSIP, and eight normal controls. All subjects were given a chest radiograph, HRCT, pulmonary function test, and blood gas analysis (Table 1). The diagnoses of IPF and NSIP were based on the international consensus statement (21). Two of the NSIP patients had inflammation and fibrotic type pneumonia (group II) and eight had interstitial fibrotic type pneumonia (group III). BAL and open -lung or video-guided thoracoscopic biopsies were performed on all IIP patients. BAL was performed at least 3 days before lung biopsy and without any immunosuppressive therapies. In normal subjects, BAL was performed on the right middle lobe. Exclusion criteria consisted of other known causes of interstitial lung disease, such as drug reactions, environmental exposures, and collagen vascular diseases. The normal controls were all healthy volunteers, free of symptoms, not taking any medications, and who had normal chest radiographs. For immunohistochemical staining, the healthy tissues of biopsies of solitary pulmonary nodules were used.
###end p 9
###begin title 10
Measurements of IL-13, IL-4, and IFN-gamma concentrations in Bronchoalveolar lavage (BAL) fluids
###end title 10
###begin p 11
###xml 43 45 43 45 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B17">17</xref>
BAL was performed as previously described (17), using a flexible fiberoptic bronchoscope (Olympus B2-10; Olympus Optical Co., Tokyo, Japan). Briefly, all study subjects were pretreated with atropine (0.5 mg) immediately before the BAL procedure. Bronchial trees were instilled four times with 50 mL of normal saline, and fluid was removed each time by gentle suction with negative pressure below 50 mmHg. The total volume of recovered fluids was measured, and the supernatant was separated from the cell pellets by centrifugation at 500xg for 5 min. The supernatants were frozen and stored at -80℃ for later use. A differential count of 500 cells was performed on slides prepared by cytocentrifugation and Diff-Quik staining (Scientific Products, Gibbstowne, NJ, U.S.A.). No complications were experienced during the BAL procedures.
###end p 11
###begin p 12
The IL-13, IL-4, and IFN-gamma levels were measured using quantitative sandwich enzyme immunoassays with ELISA kits (BD Bioscience, San Diego, CA, U.S.A.), according to the manufacturer's recommendations. The detection limits were 2.0 pg/mL, 3.5 pg/mL, and 1.0 pg/mL for IL-4, IL-13, and IFN-gamma, respectively, and values below these thresholds were assigned a value of 0 pg/mL. For validation of assay, we performed spiking experiment using 10 samples and the recovery rates of IL-4, IL-13, and IFN-gamma were 86.2+/-0.1%, 93.5+/-0.6%, 89.3+/-0.8%, respectively. The inter-assay coefficient of variability for all assays was less than 10%, and the intraassay coefficient of variability was less than 10% across the range of concentrations.
###end p 12
###begin title 13
Immunohistochemical staining
###end title 13
###begin p 14
###xml 201 202 197 198 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 203 204 199 200 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 14 18 <span type="species:ncbi:9925">goat</span>
###xml 278 284 <span type="species:ncbi:9986">rabbit</span>
###xml 336 340 <span type="species:ncbi:9925">goat</span>
###xml 439 443 <span type="species:ncbi:9925">goat</span>
###xml 642 648 <span type="species:ncbi:9986">rabbit</span>
###xml 654 658 <span type="species:ncbi:9925">goat</span>
A VectaStatin goat ABC Elite kit (Vector Laboratories, Burlingame, CA, U.S.A.) was used for immunostaining. Tissue sections (5 microm) were deparaffinized, endogenous peroxidase was blocked with 1.4% H2O2 in MeOH for 30 min, and nonspecific binding was blocked with 1.5% normal rabbit serum for 30 min. The sections were incubated with goat polyclonal antihuman IL-13 antibody (1:100, Santa Cruz Biotechnology, Santa Cruz, CA, U.S.A.) and goat polyclonal antihuman IL-13Ralpha1 and IL-13Ralpha2 antibody (1:200, R&D, Minneapolis, MN, U.S.A.) at 4℃ for 16 hr. After washing with TBS, the sections were sequentially incubated with biotinylated rabbit anti-goat immunoglobulin G (H+L) (1:200, Vector Laboratories, Burlingame, CA, U.S.A.) and avidin-biotin peroxidase complex (1:50, ABC kit, Vector Laboratories) for 30 min. The color reaction was developed with 3,3'-diaminobenzidine tetrachloride (Zymed Laboratories, South San Francisco, CA, U.S.A.), and Harris hematoxylin stain was applied as a counter stain. The intensity of immunostaining was graded from absent (-) to strongly positive (+++) for the following tissues: alveolar epithelium, bronchial epithelium, smooth muscle, alveolar macrophage, endothelial cells, and interstitium. Grading was as follows: (-), no staining; (+/-), very faintly brown; (+), faintly brown; (++), moderately brown; and (+++), dark brown. Histological sections were assessed independently by two observers who were blind to the clinical information of the study subjects.
###end p 14
###begin title 15
Statistics
###end title 15
###begin p 16
###xml 454 455 450 451 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
The SPSS/PC+ program (Chicago, IL, U.S.A.) was used for statistical analyses. Differences between groups were compared with the nonparametric Kruskal-Wallis test for continuous data. Significant relationships between groups were further analyzed using the Mann-Whitney U test. Spearman's rank correlation was used to analyze the relationships of IL-4, IL-13, and IFN-gamma concentrations to the lung functions. Differences were considered significant at P<0.05. The data are expressed as mean+/-SEM.
###end p 16
###begin title 17
RESULTS
###end title 17
###begin title 18
Clinical profiles of study subjects and cellular proportions in BAL fluids
###end title 18
###begin p 19
###xml 48 55 48 55 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T1">Table 1</xref>
###xml 318 319 318 319 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 495 496 495 496 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 506 507 506 507 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 720 721 720 721 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 149 157 <span type="species:ncbi:9606">patients</span>
###xml 428 436 <span type="species:ncbi:9606">patients</span>
###xml 625 633 <span type="species:ncbi:9606">patients</span>
###xml 643 651 <span type="species:ncbi:9606">patients</span>
The clinical and BAL profiles are summarized in Table 1. Age, smoking status, and sex ratio were comparable among the three groups. The NSIP and IPF patients had a significant reduction in forced vital capacity (FVC), total lung capacity (TLC), and diffusing capacity of carbon monoxide (DLCO) compared with controls (P<0.05). Both the cell number and percentage of neutrophils in 1 mL of BAL fluid were significantly higher in patients with NSIP and in those with IPF than in control subjects (P<0.01 and P<0.05, respectively). There were no difference in the percentages of lymphocytes and macrophages between NSIP and IPF patients, but IPF patients had a significantly higher percentage of eosinophils than controls (P<0.01).
###end p 19
###begin title 20
IL-4, IL-13, and IFN-gamma concentrations in BAL fluids
###end title 20
###begin p 21
###xml 210 211 206 207 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 269 270 261 262 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 348 349 340 341 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 357 364 349 356 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F1">Fig. 1A</xref>
###xml 632 633 618 619 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 644 645 630 631 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 748 749 734 735 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 756 763 742 749 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F1">Fig. 1B</xref>
###xml 1016 1023 988 995 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F1">Fig. 1C</xref>
###xml 1102 1103 1074 1075 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 1188 1189 1160 1161 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 1230 1231 1202 1203 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 1265 1271 1237 1243 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F2">Fig. 2</xref>
###xml 52 60 <span type="species:ncbi:9606">patients</span>
###xml 141 149 <span type="species:ncbi:9606">patients</span>
###xml 163 171 <span type="species:ncbi:9606">patients</span>
###xml 321 329 <span type="species:ncbi:9606">patients</span>
###xml 410 418 <span type="species:ncbi:9606">patients</span>
###xml 438 446 <span type="species:ncbi:9606">patients</span>
###xml 814 822 <span type="species:ncbi:9606">patients</span>
###xml 841 849 <span type="species:ncbi:9606">patients</span>
###xml 885 892 <span type="species:ncbi:9606">patient</span>
###xml 1063 1071 <span type="species:ncbi:9606">patients</span>
###xml 1255 1263 <span type="species:ncbi:9606">patients</span>
IL-13 activity was detected in the BAL fluid of all patients and in seven of the eight control subjects. The IL-13 levels were higher in IPF patients than in NSIP patients (249.0+/-83.1 vs. 137.7+/-37.9 pg/mL, P=0.032) and controls (249.0+/-83.1 vs. 49.0+/-13.1 pg/mL, P=0.012). The IL-13 levels were also higher in NSIP patients than in controls (P=0.041; Fig. 1A). IL-4 activity was detected in 12 of 16 IPF patients, eight of ten NSIP patients, and three of eight controls. The mean IL-4 level was significantly higher in the IPF and NSIP groups than in the control group (16.3+/-4.5 and 12.3+/-3.35 pg/mL vs. 4.67+/-2.28 pg/mL, P=0.008 and P=0.034, respectively). The IL-4 level was not significantly different between the IPF and NSIP groups (P>0.05; Fig. 1B). IFN-gamma activity was detected in 14 of 16 IPF patients, nine of ten NSIP patients, and seven of eight controls. Both patient groups had low INF-gamma levels compared with the control group (7.72+/-3.02 and 3.82+/-1.59 pg/mL vs. 11.32+/-3.64 pg/mL; Fig. 1C), but only the difference between NSIP patients and controls was significant (P=0.047). The IL-13 level was inversely correlated with DLCO (% pred) (n=26, r=-0.58, P=0.014) and FVC (% pred) (n=26, r=-0.47, P=0.043) in NSIP and IPF patients (Fig. 2). Neither the IL-4 nor INF-gamma level correlated with the physiological parameters (data not shown).
###end p 21
###begin title 22
Expression of IL-13 and IL-13Ralpha1/alpha2 detected by immunohistochemical staining
###end title 22
###begin p 23
###xml 559 565 547 553 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F3">Fig. 3</xref>
###xml 693 700 681 688 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T2">Table 2</xref>
###xml 814 821 794 801 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T2">Table 2</xref>
###xml 823 829 803 809 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F3">Fig. 3</xref>
###xml 127 135 <span type="species:ncbi:9606">patients</span>
###xml 152 160 <span type="species:ncbi:9606">patients</span>
###xml 549 557 <span type="species:ncbi:9606">patients</span>
###xml 661 669 <span type="species:ncbi:9606">patients</span>
###xml 683 691 <span type="species:ncbi:9606">patients</span>
###xml 798 805 <span type="species:ncbi:9606">patient</span>
Immunohistochemical staining of IL-13, IL-13Ralpha1, and IL-13Ralpha2 was performed in the lung tissues of controls (n=4), IPF patients (n=6), and NSIP patients showing fibrosis (n=6). To avoid the smoking effect, never smokers were selected from the study subjects. Control subjects had undergone a lobectomy to remove localized solitary pulmonary nodules (two lung cancer and two tuberculoma). Both IL-13 and IL-13Ralpha1 were strongly expressed in the bronchial epithelial cells, alveolar macrophages, endothelial cells, and smooth muscle of all patients (Fig. 3), although semiquantitative evaluation showed that their intensities were much stronger in IPF patients than in NSIP patients (Table 2). IL-13Ralpha2 showed the same pattern of expression as IL-13Ralpha1 but weaker staining in both patient groups (Table 2, Fig. 3). Neither IL-13Ralpha1 nor IL-13Ralpha2 expression was detected in the four control lung tissues.
###end p 23
###begin title 24
DISCUSSION
###end title 24
###begin p 25
###xml 351 352 347 348 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B2">2</xref>
###xml 353 354 349 350 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B4">4</xref>
###xml 490 491 486 487 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B4">4</xref>
###xml 712 714 708 710 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B24">24</xref>
###xml 89 97 <span type="species:ncbi:9606">patients</span>
###xml 288 296 <span type="species:ncbi:9606">patients</span>
###xml 321 329 <span type="species:ncbi:9606">patients</span>
###xml 414 422 <span type="species:ncbi:9606">patients</span>
###xml 582 590 <span type="species:ncbi:9606">patients</span>
###xml 654 662 <span type="species:ncbi:9606">patients</span>
###xml 676 684 <span type="species:ncbi:9606">patients</span>
###xml 793 800 <span type="species:ncbi:9606">patient</span>
We demonstrated that IL-4 and IL-13 levels were higher in the BAL fluids of NSIP and IPF patients than in that of healthy subjects and that INF-gamma levels were lowest in the NSIP groups. These findings suggest that there is a predominance of Th2 over Th1 cytokines in the lungs of NSIP patients, as demonstrated in IPF patients of previous studies (2-4). In the present study, the mean IL-13 level was higher in patients than in controls, consistent with the reports of Jakubzick et al. (4), who demonstrated that IL-13 gene expression was higher in lung biopsies of IPF and NSIP patients. However, in our study, the mean IL-13 level was higher in IPF patients than in NSIP patients, whereas Jakubzick et al. (24) reported no significant differences in IL-13 gene expression between the two patient groups. In both studies, IL-4 levels were comparable between the two groups.
###end p 25
###begin p 26
###xml 166 172 166 172 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F2">Fig. 2</xref>
###xml 266 274 <span type="species:ncbi:9606">patients</span>
In addition, the IL-13 (and not IL-4) level was inversely correlated with physiological derangement, including decreases in DLCO and lung volume. This novel finding (Fig. 2) suggests that IL-13, rather than IL-4, may be associated with functional derangement in the patients with IPF and NSIP.
###end p 26
###begin p 27
###xml 245 247 245 247 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B22">22</xref>
###xml 405 407 405 407 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B23">23</xref>
###xml 739 750 739 750 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pseudomonas</italic>
###xml 820 822 820 822 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B24">24</xref>
###xml 871 873 871 873 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B25">25</xref>
###xml 911 913 911 913 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B26">26</xref>
###xml 941 943 941 943 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B27">27</xref>
###xml 313 317 <span type="species:ncbi:10090">mice</span>
###xml 358 362 <span type="species:ncbi:10090">mice</span>
###xml 597 605 <span type="species:ncbi:9606">patients</span>
###xml 683 688 <span type="species:ncbi:9606">human</span>
Several studies on animal models have suggested a comprehensive role for IL-13, rather than IL-4, in pulmonary fibrosis. Neutralization of IL-13, but not IL-4 alone, attenuated pulmonary fibrosis in a bleomycin-induced pulmonary fibrosis model (22). In response to fluorescein isothiocyanate exposure, IL-4 (-/-) mice developed fibrosis, whereas IL-13 (-/-) mice were significantly resistant to fibrosis (23). These results, and the fact that IPF is associated with more fibrotic lung lesion than is NSIP, suggest that IL-13, rather than IL-4, may be responsible for the degree of fibrosis in IIP patients, as seen in our study. Indeed, administrating a chimeric protein, comprising human IL-13 and a truncated version of an exotoxin from Pseudomonas (IL13-PE), as a therapeutic agent significantly attenuated fibrosis (24). IL-13 may induce pulmonary fibrosis directly (25) or indirectly through TGF (beta)-1 (26) and several types of MMP (27).
###end p 27
###begin p 28
###xml 74 76 66 68 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B11">11</xref>
###xml 392 394 372 374 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B28">28</xref>
###xml 645 646 617 618 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B4">4</xref>
###xml 601 609 <span type="species:ncbi:9606">patients</span>
Receptor binding chains for IL-13 include IL-13 Ralpha1 and IL-13Ralpha2 (11). IL-13 Ralpha1 binds IL-13 with low affinity, whereas the co-expression of IL-13Ralpha1 and IL-4Ralpha results in the formation of a high-affinity receptor signaling complex that renders a variety of cells (e.g., mast, eosinophil, endothelial, fibroblast, smooth muscle, and epithelial cells) responsive to IL-13 (28). In the present study, both IL-13Ralpha1 and IL-13Ralpha2 were expressed in the bronchial epithelial cells, alveolar macrophages, endothelial cells, and smooth muscles and interstitium of all IPF and NSIP patients, consistent with Jakubzick et al. (4), who found that both proteins were strongly expressed in the interstitium of the lung and that IL-13Ralpha2 was also strongly expressed in the lung epithelium and in mononuclear cells.
###end p 28
###begin p 29
###xml 130 132 122 124 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B10">10</xref>
###xml 134 136 126 128 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B11">11</xref>
###xml 240 242 228 230 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B10">10</xref>
###xml 244 246 232 234 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B11">11</xref>
###xml 374 376 354 356 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B29">29</xref>
###xml 851 853 819 821 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B30">30</xref>
###xml 1126 1128 1080 1082 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B30">30</xref>
###xml 1249 1251 1196 1198 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B12">12</xref>
###xml 1253 1255 1200 1202 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B29">29</xref>
###xml 490 498 <span type="species:ncbi:9606">patients</span>
###xml 621 629 <span type="species:ncbi:9606">patients</span>
The effects of IL-13 are mediated by a complex receptor system, which includes IL-4Ralpha and IL-13Ralpha1, via STAT6 activation (10, 11). IL-13Ralpha2 has a short cytoplasmic tail without intracellular signaling motifs that bind to STAT6 (10, 11) thus, this receptor was expected to compete with the IL-4Ralpha-/IL-13Ralpha1 complex and dampen the IL-13-mediated response (29). At present, however, it is not clear why the greatly increased expression of IL-13Ralpha2, particularly in IPF patients, fails to curtail the profibrotic actions of IL-13. It is possible that the natural antagonism of IL-13Ralpha2 is lost in patients with IIP as a result of post-translational modifications of this decoy receptor. Or perhaps, as a result of these modifications, the IL-13Ralpha2 subunit takes on an abnormal signaling role in IPF. Fichtner-Feigl et al. (30) recently demonstrated that IL-13 is involved in the activation of the TGFbeta1 promoter via IL-13Ralpha2. Furthermore, blocking IL-13 Ralpha2 signaling with siRNA led to a down regulation of TGFbeta1 production and collagen deposition in bleomycin-induced lung fibrosis (30). This result indicates that IL-13Ralpha2 can augment fibrosis via TGFbeta modulation, which contradicts other studies (12, 29).
###end p 29
###begin p 30
###xml 629 635 609 615 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F2">Fig. 2</xref>
###xml 637 644 617 624 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T2">Table 2</xref>
###xml 323 329 <span type="species:ncbi:9606">people</span>
###xml 418 426 <span type="species:ncbi:9606">patients</span>
###xml 439 447 <span type="species:ncbi:9606">patients</span>
###xml 565 572 <span type="species:ncbi:9606">patient</span>
###xml 909 917 <span type="species:ncbi:9606">patients</span>
The present study did not directly evaluate the role of IL-13Ralpha2 as a protector against or inducer of fibrosis in IIP. We demonstrated the increased expression of IL-13Ralpha1 and IL-13Ralpha2 in the two types of IIP, and no expression in controls, indicating that both types of receptors are induced in the tissues of people with IIP. However, the intensity of these two receptors was significantly lower in NSIP patients than in IPF patients. Furthermore, IL-13Ralpha1 was strongly expressed in the epithelium, smooth muscle, and alveolar macrophages of both patient groups, whereas IL-13Ralpha2 was only weakly expressed (Fig. 2, Table 2), suggesting that differences in the expression of IL-13Ralpha1 and IL-13Ralpha2 may help explain the varying degrees of lung fibrosis between the two conditions. A possible limitation of our study is that the differences in IL-13 values for the BAL fluids of IIP patients and controls (as determined by ELISA) may have been affected by the presence of soluble isoforms of the IL-13 receptor subunits. There are many potential complications for measuring cytokine proteins in whole lung homogenates; for example, the presence of soluble decoy receptors and post-translational modifications of the cytokine proteins can render the proteins undetectable by ELISA. Small numbers of NSIP and IPF in this study also regarded another limitation.
###end p 30
###begin p 31
###xml 120 128 <span type="species:ncbi:9606">patients</span>
###xml 230 238 <span type="species:ncbi:9606">patients</span>
###xml 309 317 <span type="species:ncbi:9606">patients</span>
In conclusion, IL-13 levels were significantly elevated and inversely correlated with DLCO and FVC in both IPF and NSIP patients. Moreover, IL-13Ralpha1 and IL-13Ralpha2 were strongly expressed in the lung tissues of IPF and NSIP patients. However, IL-13 and the two receptors were more strongly expressed in patients with IPF than in those with NSIP. These results suggest that the elevation of IL-13 elevation and the concomitant expression of IL-13Ralpha1 and IL-13Ralpha2 may be associated with the pathogenesis of both IPF and NSIP.
###end p 31
###begin title 32
ACKNOWLEDGMENTS
###end title 32
###begin p 33
The authors are indebted to, Myong-ran Lee, and Eunyoung Kim for their excellent technical support throughout the study. The authors express thanks to at least two professional editors, both native speakers of English for their kind editing for grammar and topographic error .
###end p 33
###begin p 34
The DNA samples were generously provided by the Soonchunhyang University, Bucheon Hospital Biobank, a member of the National Biobank of Korea, supported by the Ministry of Health, Welfare and Family Affairs, Republic of Korea.
###end p 34
###begin p 35
###xml 75 122 75 122 <funding-source xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ministry of Health &amp; Welfare, Republic of Korea</funding-source>
###xml 124 147 124 147 <award-id xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">01-PJ10-PG6-01GN14-0003</award-id>
###xml 160 184 160 184 <funding-source xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Soonchunhyang University</funding-source>
###xml 202 210 202 210 <award-id xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">20030198</award-id>
This study was supported by a grant from the Korean Health 21 R&D project, Ministry of Health & Welfare, Republic of Korea (01-PJ10-PG6-01GN14-0003) and by the Soonchunhyang University Research Fund (# 20030198).
###end p 35
###begin article-title 36
Idiopathic pulmonary fibrosis: clinical relevance of pathologic classification
###end article-title 36
###begin article-title 37
###xml 93 101 <span type="species:ncbi:9606">patients</span>
###xml 141 144 <span type="species:ncbi:31658">CFA</span>
A type 2 (Th2-like) pattern of immune response predominates in the pulmonary interstitium of patients with cryptogenic fibrosing alveolitis (CFA)
###end article-title 37
###begin article-title 38
Different cytokine profiles in cryptogenic fibrosing alveolitis and fibrosing alveolitis associated with systemic sclerosis: a quantitative study of open lung biopsies
###end article-title 38
###begin article-title 39
Augmented pulmonary IL-4 and IL-13 receptor subunit expression in idiopathic interstitial pneumonia
###end article-title 39
###begin article-title 40
###xml 68 76 <span type="species:ncbi:9606">patients</span>
Cytokine profile and proteome analysis in bronchoalveolar lavage of patients with sarcoidosis, pulmonary fibrosis associated with systemic sclerosis and idiopathic pulmonary fibrosis
###end article-title 40
###begin article-title 41
###xml 40 46 <span type="species:ncbi:10090">murine</span>
Lung interleukin-4 gene expression in a murine model of bleomycin-induced pulmonary fibrosis
###end article-title 41
###begin article-title 42
Pulmonary expression of interleukin-13 causes inflammation, mucus hypersecretion, subepithelial fibrosis, physiologic abnormalities and eotaxin production
###end article-title 42
###begin article-title 43
Cloning and characterization of a binding subunit of the interleukin 13 receptor that is also a component of the interleukin 4 receptor
###end article-title 43
###begin article-title 44
###xml 31 36 <span type="species:ncbi:9606">human</span>
###xml 68 73 <span type="species:ncbi:10090">mouse</span>
Reconstitution of a functional human type II IL-4/IL-13 receptor in mouse B cells: demonstration of species specificity
###end article-title 44
###begin article-title 45
Structure of and signal transduction through interleukin-4 and interleukin-13 receptors
###end article-title 45
###begin article-title 46
###xml 4 10 <span type="species:ncbi:10090">murine</span>
###xml 92 98 <span type="species:ncbi:10090">murine</span>
The murine IL-13 receptor alpha 2: molecular cloning, characterization, and comparison with murine IL-13 receptor alpha 1
###end article-title 46
###begin article-title 47
Regulation and function of the interleukin 13 receptor alpha 2 during a T helper cell type 2-dominant immune response
###end article-title 47
###begin article-title 48
High-Resolution computed tomography features of nonspecific interstitial pneumonia and usual interstitial pneumonia
###end article-title 48
###begin article-title 49
Histopathologic variability in usual and nonspecific interstitial pneumonias
###end article-title 49
###begin article-title 50
Physiology is a stronger predictor of survival than pathology in fibrotic interstitial pneumonia
###end article-title 50
###begin article-title 51
Nonspecific interstitial pneumonia/fibrosis: clinical manifestations, histologic and radiologic features
###end article-title 51
###begin article-title 52
Increased levels of interleukin-6 are associated with lymphocytosis in bronchoalveolar lavage fluids of idiopathic nonspecific interstitial pneumonia
###end article-title 52
###begin article-title 53
###xml 70 78 <span type="species:ncbi:9606">patients</span>
Increased levels of interleukin-18 in bronchoalveolar lavage fluid of patients with idiopathic nonspecific interstitial pneumonia
###end article-title 53
###begin article-title 54
High-BAL fluid concentrations of RANTES in nonspecific interstitial pneumonia compared with usual interstitial pneumonia
###end article-title 54
###begin article-title 55
###xml 56 64 <span type="species:ncbi:9606">patients</span>
Comparison of BALF concentrations of ENA-78 and IP10 in patients with idiopathic pulmonary fibrosis and nonspecific interstitial pneumonia
###end article-title 55
###begin article-title 56
Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society, and the European Respiratory Society
###end article-title 56
###begin article-title 57
Interaction of IL-13 and C10 in the pathogenesis of bleomycin-induced pulmonary fibrosis
###end article-title 57
###begin article-title 58
###xml 104 108 <span type="species:ncbi:10090">mice</span>
Protection from fluorescein isothiocyanate-induced fibrosis in IL-13-deficient, but not IL-4-deficient, mice results from impaired collagen synthesis by fibroblasts
###end article-title 58
###begin article-title 59
Therapeutic targeting of IL-4- and IL-13-responsive cells in pulmonary fibrosis
###end article-title 59
###begin article-title 60
An IL-13 inhibitor blocks the development of hepatic fibrosis during a T-helper type 2-dominated inflammatory response
###end article-title 60
###begin article-title 61
Interleukin-13 induces tissue fibrosis by selectively stimulating and activating transforming growth factor beta(1)
###end article-title 61
###begin article-title 62
Overlapping and enzyme-specific contributions of matrix metalloproteinases-9 and -12 in IL-13-induced inflammation and remodeling
###end article-title 62
###begin article-title 63
###xml 16 21 <span type="species:ncbi:9606">human</span>
Localization of human interleukin 13 receptor in non-haematopoietic cells
###end article-title 63
###begin article-title 64
Cytokine regulation of IL-13Ralpha2 and IL-13Ralpha1 in vivo and in vitro
###end article-title 64
###begin article-title 65
IL-13 signaling through the IL-13 alpha(2) receptor is involved in induction of TGF-beta(1) production and fibrosis
###end article-title 65
###begin p 66
###xml 68 76 <span type="species:ncbi:9606">patients</span>
IL-4, IL-13, and IFN-gamma levels in the BAL fluids of IPF and NSIP patients and of normal controls. Horizontal bars represent the mean levels of the three groups.
###end p 66
###begin p 67
###xml 245 246 245 246 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 282 283 282 283 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 71 79 <span type="species:ncbi:9606">patients</span>
###xml 146 154 <span type="species:ncbi:9606">patients</span>
Correlation between IL-13 levels and FVC (% pred) and DLCO (% pred) in patients with IPF and NSIP. Open and closed circles represent NSIP and IPF patients, respectively. IL-13 showed a significant inverse correlation with FVC (% pred) (r=-0.47, P=0.043) and DLCO (% pred) (r=-0.58, P=0.014).
###end p 67
###begin p 68
###xml 186 187 178 179 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 238 239 230 231 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 317 318 309 310 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</bold>
###xml 343 344 335 336 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">D</bold>
###xml 360 361 352 353 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E</bold>
###xml 381 382 373 374 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">F</bold>
###xml 500 501 488 489 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">G</bold>
###xml 575 576 559 560 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">H</bold>
###xml 599 600 583 584 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 608 609 592 593 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 618 619 602 603 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</bold>
###xml 621 622 605 606 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">F</bold>
###xml 623 624 607 608 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">H</bold>
###xml 637 638 621 622 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">D</bold>
###xml 640 641 624 625 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E</bold>
###xml 100 108 <span type="species:ncbi:9606">patients</span>
###xml 391 399 <span type="species:ncbi:9606">patients</span>
###xml 490 498 <span type="species:ncbi:9606">patients</span>
###xml 565 573 <span type="species:ncbi:9606">patients</span>
Immunohistochemical analysis of IL-13 and IL-13Ralpha1/IL-13Ralpha2 expression in lung tissues from patients with IPF and from controls. IL-13 was only negligibly expressed in controls (A) but was strongly expressed in the smooth muscle (B), bronchial epithelium, especially the hyperplastic regenerating epithelium (C), alveolar macrophages (D), endothelium (E), and interstitum (F) of IPF patients. IL-13Ralpha1 was strongly expressed by the bronchial epithelium and smooth muscle of IPF patients (G). IL-13Ralpha2 was weakly expressed in the same regions of IPF patients (H). Magnification: x20 (A), x40 (B), x100 (C, F-H), and x200 (D, E).
###end p 68
###begin p 69
Demographic characteristics, lung function and bronchoalveolar lavage fluid (BALF) profiles of the study subjects
###end p 69
###begin p 70
Data are presents as mean+/-SEM.
###end p 70
###begin p 71
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">*</sup>
###xml 1 2 1 2 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 38 44 38 39 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8224;</sup>
###xml 44 45 39 40 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
*P<0.05 compared with normal control; daggerP<0.01 compared with normal control.
###end p 71
###begin p 72
IPF, idiopathic pulmonary fibrosis; CS, current smoker; ES, ex-smoker; NS, never-smoker; TLC, total lung capaciy; FVC, forced vital capacity; DLCO, diffusing capacity of carbon monoxide; NSIP, nonspecific interstitial pneumonia.
###end p 72
###begin p 73
Immunostaining for IL-13, IL-13Ralpha1, and IL-13Ralpha2 from IPF, NSIP and normal controls lung specimens
###end p 73
###begin p 74
Data are presented as - (absent) to +++ (intense) staining.
###end p 74
###begin p 75
IPF, idiopathic pulmonary fibrosis; NSIP, nonspecific interstitial pneumonia.
###end p 75

